NEW HAVEN, Conn. and TOKYO, Oct. 3 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) today announced that it has entered...
NEW HAVEN, Conn. and TOKYO, Sept. 21 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) today announced that it has...
NEW HAVEN, Conn., and MARSEILLE, France, Sept. 12 /PRNewswire-FirstCall/ -- Privately-held Ipsogen SAS and Genaissance Pharmaceuticals, Inc...
- Increases Presence in EU Ag Genotyping Market - NEW HAVEN, Conn., Aug. 23 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc...
- Will Address EU Mandate for Sheep-Breeding Programs That Confer Resistance to Scrapie - NEW HAVEN, Conn., Aug. 11 /PRNewswire-FirstCall/...
Genaissance Pharmaceuticals Enters into HAP(TM) Technology License Agreement with Organon NEW HAVEN, Conn. and OSS, Netherlands, July 18...
Clinical Data to Acquire Genaissance Pharmaceuticals Combined Company to Deliver Industry-Defining Theranostics NEWTON, Mass., and NEW HAVEN...
Clinical Data, Inc. (NASDAQ:CLDA) and Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) today announced that they have signed an agreement for...
Genaissance to Provide Pharmacogenetic Support to INC Research, Its First CRO Partner NEW HAVEN, Conn., June 7 /PRNewswire-FirstCall/...
Genaissance Reports First Quarter 2005 Results Company Cites Progress In Key Areas, Including Recent Increase In Cash Reserves NEW HAVEN, Conn...
Genaissance Pharmaceuticals Comments on Stock Activity NEW HAVEN, Conn., April 28 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc...
Genaissance Pharmaceuticals to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference NEW HAVEN, Conn., April 27...
Support
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads